Regencell Bioscience Holdings Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Yat-Gai Au

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	10.3yrs
CEO ownership	81.2%
Management average tenure	2.1yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Regencell Bioscience Holdings' (NASDAQ:RGC) Cash Burn Situation

Nov 18

Slow And Steady Wins The Race With Regencell Bioscience

Aug 16

CEO

Yat-Gai Au (50 yo)

10.3yrs

Tenure

Mr. Yat-Gai Au serves as the Chief Financial Officer of Armitage Technologies Holding Ltd. Mr. Au served as Compliance Officer and Executive Director of Armitage Technologies Holding Ltd. He joined Armitag...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yat-Gai Au	Founder	no data	no data	81.16% $ 63.2m
Michelle Chan	Financial Controller	2.1yrs	no data	no data
Wai Hong Chung	COO & Chief Strategy Officer	2.8yrs	US$245.64k	no data
Antonia Assang	Senior Vice President of Project Management	no data	no data	no data
Yat-Pui Au	Chief Business Officer	1.3yrs	no data	no data

2.1yrs

Average Tenure

49yo

Average Age

Experienced Management: RGC's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yat-Gai Au	Founder	10.3yrs	no data	81.16% $ 63.2m
Yee Wah Hui	Independent Director	2.8yrs	no data	no data
Paul J. Niewiadomski	Independent Director	2.8yrs	no data	no data
Wing-Yan Lo	Independent Director	2.4yrs	no data	no data

2.8yrs

Average Tenure

51.5yo

Average Age

Experienced Board: RGC's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Regencell Bioscience Holdings Management

Management criteria checks 1/4

Key information

Recent management updates

Regencell Bioscience Holdings Limited Announces the Resignation of Yi-Chung Chao as Chief Medical Officer, with Effect from December 28, 2022

High number of new and inexperienced directors

Founder recently bought US$886k worth of stock

Founder recently bought US$1.2m worth of stock

High number of new and inexperienced directors

Regencell Bioscience Holdings Limited Announces Resignation of Tien Hsiang Chau as Chief Financial Officer

Recent updates

New major risk - Share price stability

New minor risk - Market cap size

Here's Why We're Not Too Worried About Regencell Bioscience Holdings' (NASDAQ:RGC) Cash Burn Situation

Regencell Bioscience Holdings Limited Announces the Resignation of Yi-Chung Chao as Chief Medical Officer, with Effect from December 28, 2022

High number of new and inexperienced directors

Regencell Bioscience Holdings Limited Announces its Standardized Formulae Shows Reduce ADHD and ASD Symptoms in Interim Results of its Second Efficacy Trial

Slow And Steady Wins The Race With Regencell Bioscience

Founder recently bought US$886k worth of stock

Regencell Bioscience Holdings Limited Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness of Its Investigational Liquid-Formula Rgc-Cov19tm in Eliminating Mild to Moderate Covid-19 Symptoms Within the 6-Day Treatment Period

Founder recently bought US$1.2m worth of stock

High number of new and inexperienced directors

Regencell Bioscience Holdings Limited Announces Resignation of Tien Hsiang Chau as Chief Financial Officer

Founder recently bought US$542k worth of stock

Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19 Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial

Less than half of directors are independent

Independent Director Cheung Ming Wong has left the company

Regencell Bioscience Holdings Limited has completed an IPO in the amount of $21.85 million.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age